|
1
|
Moreira RN, Santos CR, Lima NL, Verli FD
and Marinho SA: Oral and cutaneous melanoma: similarities and
differences. J Clin Med Res. 2:155–158. 2010.
|
|
2
|
Yang X, Ren GX, Zhang CP, et al: Neck
dissection and post-operative chemotherapy with dimethyl triazeno
imidazole carboxamide and cisplatin protocol are useful for oral
mucosal melanoma. BMC Cancer. 10:6232010.
|
|
3
|
Barker BF, Carpenter WM, Daniels TE, et
al: Oral mucosal melanomas: the WESTOP Banff workshop proceedings.
Western Society of Teachers of Oral Pathology Oral Surg Oral Med
Oral Pathol Oral Radiol Endod. 83:672–679. 1997.
|
|
4
|
Bachar G, Loh KS, O’Sullivan B, et al:
Mucosal melanomas of the head and neck: experience of the Princess
Margaret Hospital. Head Neck. 30:1325–1331. 2008.
|
|
5
|
Guevara-Canales JO, Gutiérrez-Morales MM,
Sacsaquispe-Contreras SJ, Sánchez-Lihón J and Morales-Vadillo R:
Malignant melanoma of the oral cavity. Review of the literature and
experience in a Peruvian Population. Med Oral Patol Cir Bucal.
17:e206–e211. 2012.
|
|
6
|
Silverman S: Etiology and predisponing
factors. Oral Cancer. 5th edition. BC Decker Inc; Hamilton, London:
pp. 155–157. 2003
|
|
7
|
Hashemi Pour MS: Malignant melanoma of the
oral cavity: a review of literature. Indian J Dent Res. 19:47–51.
2008.
|
|
8
|
Jahanshahi P, Nasr N, Unger K, Batouli A
and Gagnon GJ: Malignant melanoma and radiotherapy: past myths,
excellent local control in 146 studied lesions at Georgetown
University, and improving future management. Front Oncol.
2:1672012.
|
|
9
|
Greenberg MS and Glic KM: Pigmented
lesions of the oral mucosa. Burket’s Oral Medicine. 9th edition. BC
Decker; Hamilton: pp. 131–132. pp. 214–215. 2003
|
|
10
|
Prabhu SR, Wilson DF and Daftary DK: Oral
and salivary gland neoplasms in tropical populations. Oral Diseases
in the Tropics. Oxford University Press; New York: pp. 460–461.
1992
|
|
11
|
Neville BW, Damm D, Allen CM and Bouquot
JE: Epithelial pathology. Oral and Maxillofacial Pathology. 2nd
edition. WB Saunders; Philadelphia: pp. 334pp. 376–380. 2002
|
|
12
|
van der Waal RI, Snow GB, Karim AB and van
der Waal I: Primary malignant melanoma of the oral cavity: a review
of eight cases. Br Dent J. 176:185–188. 1994.
|
|
13
|
Robertson GR, DeFiebre BK and Firtell DN:
Primary malignant melanoma of the mouth. J Oral Surg. 37:349–352.
1979.
|
|
14
|
Rapidis AD, Apostolidis C, Vilos G and
Valsamis S: Primary malignant melanoma of the oral mucosa. J Oral
Maxillofac Surg. 61:1132–1139. 2003.
|
|
15
|
Cebrián Carretero JL, Chamorro Pons M and
Montesdeoca N: Melanoma of the oral cavity. Review of the
literature. Med Oral. 6:371–375. 2001.
|
|
16
|
Lopez-Graniel CM, Ochoa-Carrillo FJ and
Meneses-García A: Malignant melanoma of the oral cavity: diagnosis
and treatment experience in a Mexican population. Oral Oncol.
35:425–430. 1999.
|
|
17
|
Rapini RP: Oral melanoma: diagnosis and
treatment. Semin Cutan Med Surg. 16:320–322. 1997.
|
|
18
|
Wood NK and Goaz PW: Solitary red lesions;
intraoral brownish, bluish, or black conditions. Differential
Diagnosis of Oral and Maxillofacial lesions. 5th edition. Mosby;
United States: pp. 67–68. pp. 1901997
|
|
19
|
Liebross RH, Morrison WH, Garden AS and
Ang KK: 50 Mucosal melanoma of the head and neck. Int J Radiol
Oncol. 39:159–162. 1997.
|
|
20
|
Doval DC, Rao CR, Saitha KS, et al:
Malignant melanoma of the oral cavity: report of 14 cases from a
regional cancer centre. Eur J Surg Oncol. 22:245–249. 1996.
|
|
21
|
Nandapalan V, Roland NJ, Helliwell TR, et
al: Mucosal melanoma of the head and neck. Clin Otolaryngol Allied
Sci. 23:107–116. 1998.
|
|
22
|
Ord RA and Blanchaert RH: The dentist’s
role in diagnosis, management, rehabilitation and prevention. Oral
Cancer Qintessence, Chicago: pp. 75–76. 1999
|
|
23
|
Takagi M, Ishikawa G and Mori W: Primary
malignant melanoma of the oral cavity in Japan. With special
reference to mucosal melanosis. Cancer. 34:358–370. 1974.
|
|
24
|
Curtin JA, Fridlyand J, Kageshita T, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005.
|
|
25
|
Maldonado JL, Fridlyand J, Patel H, et al:
Determinants of BRAF mutations in primary melanomas. J Natl Cancer
Inst. 95:1878–1890. 2003.
|
|
26
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006.
|
|
27
|
Beadling C, Jacobson-Dunlop E, Hodi FS, et
al: KIT gene mutations and copy number in melanoma subtypes. Clin
Cancer Res. 14:6821–6828. 2008.
|
|
28
|
Kong Y, Si L, Zhu Y, et al: Large-scale
analysis of KIT aberrations in Chinese patients with melanoma. Clin
Cancer Res. 17:1684–1691. 2011.
|
|
29
|
Hodi FS, Corless CL, Giobbie-Hurder A, et
al: Imatinib for melanomas harboring mutationally activated or
amplified KIT arising on mucosal, acral, and chronically
sun-damaged skin. J Clin Oncol. 31:3182–3190. 2013.
|
|
30
|
Chi Z, Li S, Sheng X, et al: Clinical
presentation, histology, and prognoses of malignant melanoma in
ethnic Chinese: a study of 522 consecutive cases. BMC Cancer.
11:852011.
|
|
31
|
Shoo BA and Kashani-Sabet M: Melanoma
arising in African-, Asian-, Latino- and Native-American
populations. Semin Cutan Med Surg. 28:96–102. 2009.
|
|
32
|
Turri-Zanoni M, Medicina D, Lombardi D, et
al: Sinonasal mucosal melanoma: Molecular profile and therapeutic
implications from a series of 32 cases. Head Neck. 35:1066–1077.
2013.
|
|
33
|
Govindarajan B, Bai X, Cohen C, et al:
Malignant transformation of melanocytes to melanoma by constitutive
activation of mitogen-activated protein kinase kinase (MAPKK)
signaling. J Biol Chem. 278:9790–9795. 2003.
|
|
34
|
Satyamoorthy K, Li G, Gerrero MR, et al:
Constitutive mitogen-activated protein kinase activation in
melanoma is mediated by both BRAF mutations and autocrine growth
factor stimulation. Cancer Res. 63:756–759. 2003.
|
|
35
|
Solit DB, Garraway LA, Pratilas CA, et al:
BRAF mutation predicts sensitivity to MEK inhibition. Nature.
439:358–362. 2006.
|
|
36
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002.
|
|
37
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008.
|
|
38
|
Wong CW, Fan YS, Chan TL, et al; Cancer
Genome Project. BRAF and NRAS mutations are uncommon in melanomas
arising in diverse internal organs. J Clin Pathol. 58:640–644.
2005.
|
|
39
|
Poynter JN, Elder JT, Fullen DR, et al:
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma
Res. 16:267–273. 2006.
|
|
40
|
Saldanha G, Potter L, Daforno P and
Pringle JH: Cutaneous melanoma subtypes show different BRAF and
NRAS mutation frequencies. Clin Cancer Res. 12:4499–4505. 2006.
|
|
41
|
Lennartsson J, Jelacic T, Linnekin D and
Shivakrupa R: Normal and oncogenic forms of the receptor tyrosine
kinase kit. Stem Cells. 23:16–43. 2005.
|
|
42
|
Rivera RS, Nagatsuka H, Gunduz M, et al:
C-kit protein expression correlated with activating mutations in
KIT gene in oral mucosal melanoma. Virchows Arch. 452:27–32.
2008.
|
|
43
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006.
|
|
44
|
Beadling C, Jacobson-Dunlop E, Hodi FS, et
al: KIT gene mutations and copy number in melanoma subtypes. Clin
Cancer Res. 14:6821–6828. 2008.
|
|
45
|
Smyth E and Carvajal R: Treatment of
Metastatic Melanoma: A New World Opens. Skin Cancer Foundation
Journal. 29:46–49. 2011.
|
|
46
|
Buery RR, Siar CH, Katase N, et al: NRAS
and BRAF mutation frequency in primary oral mucosal melanoma. Oncol
Rep. 26:783–787. 2011.
|
